Predix completes enrollment in PRX-00023 anxiety trial

By Elaine Rigoli

Tampa, Fla., May 24 - Predix Pharmaceuticals Holdings, Inc., which recently announced a definitive agreement to merge with EPIX Pharmaceuticals, Inc., announced that it has completed enrollment for its first phase 3 trial of PRX-00023.

Predix said the eight-week, double-blind, placebo-controlled, multi-center study has enrolled about 310 patients with moderate-to-severe generalized anxiety disorder.

Subjects will be randomized equally into one of two arms: a placebo arm or a PRX-00023 treatment arm, in which patients receive a dose of 40 mg once daily for three days followed by 80 mg once daily for the remainder of the study, according to a news release.

PRX-00023 represents a non-azapirone class of 5-HT1A agonists discovered using the company's proprietary G-protein coupled receptors modeling, screening and lead optimization technology.

Predix is a pharmaceutical company located in Lexington, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.